Document Detail

Effects of zoledronate in the repair of chronically infarcted rat myocardium.
MedLine Citation:
PMID:  21052019     Owner:  NLM     Status:  In-Process    
Zoledronate (Zol), one of the class of bisphophonate drugs, is commonly used to treat postmenopausal osteoporosis. Treatment of liposomal bisphosphonates has been shown to worsen myocardial infarct repair in an experimental model. The purpose of this study was to investigate the effect of Zol in the repair of chronically infarcted myocardium without liposomal encapsulation to mimic the clinical setting. Zol (20 μg/kg, a dose known to treat experimental osteoporosis in rats, n = 15) was administered subcutaneously to female Sprague-Dawley rats 1 day before coronary artery ligation. Rats receiving phosphate-buffered saline (n = 12) were used as controls. Left ventricular function, infarct size, and remodeling were studied at 4 weeks postinfarction. Zol pretreatment did not affect left ventricular ejection fraction in hearts with myocardial infarction (49.5 ± 1.4% in Zol; 50.6 ± 2.1% in phosphate-buffered saline). Infarct size was similar in Zol versus untreated hearts (34.2% ± 2.9% in Zol; 33.4% ± 2.9% in phosphate-buffered saline). Left ventricular cavity volume and circumference, infarct thickness, and expansion index were comparable between the groups. To investigate a potential effect of Zol on tissue macrophage infiltration after myocardial infarction, heart specimens were harvested 48 hours postinfarction and sections were immunostained with CD68 antibody, a macrophage-specific marker. Results of macrophage immunostaining revealed that the level of tissue macrophage infiltration was similar between groups. In conclusion, administration of Zol before myocardial infarction had no adverse effects on cardiac contractile function, infarct size, or remodeling. These results suggest that treatment of Zol given before the onset of myocardial infarction does not cause worsening of infarct repair.
Hyosook Hwang; Sharon L Hale; Justin Leeka; Robert A Kloner
Related Documents :
11751719 - Decreased nitric oxide availability in normotensive and hypertensive rats with failing ...
14557999 - Needles to promote ventricular blood into the ischemic myocardium applied in a rat hear...
7994079 - Elastic extracellular matrix of the embryonic chick heart: an immunohistological study ...
15383639 - Angiotensin ii type 2 receptor gene transfer elicits cardioprotective effects in an ang...
18639559 - Resveratrol reduces infarct size and improves ventricular function after myocardial isc...
11343419 - Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remode...
18078029 - Magnetic resonance imaging in coronary artery bypass surgery--improvement of global and...
7752669 - Physical activity in the cardiac patient.
23103659 - Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanopart...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  56     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2011-04-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  604-9     Citation Subset:  IM    
The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cardioprotective effects of 2-octynyladenosine (YT-146) in ischemic/reperfused rat hearts.
Next Document:  Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensiv...